Skip to main content

Table 2 MenC disease casesa in the Netherlands per year, age group, and among vaccinees

From: Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

Year

Total

Incidence rateb

Age groups

   
   

0-11 mths

1-4 yrs

5-9 yrs

10-14 yrs

15-19 yrs

20-24 yrs

25-29 yrs

≥ 30 yrs

among vaccinees

2000

105

0.7

2

22

15

11

18

9

4

24

n.a.

2001

276

1.7

23

50

27

39

65

15

9

48

n.a.

2002 c

222

1.4

13

39

30

26

47

17

5

45

0c

2003 d

42

0.3

11

6

0

1

0

6

0

18

0

2004

17

0.1

1

1

1

0

0

1

2

11

0

2005

4

0.03

0

0

0

0

0

0

0

4

0

2006

4

0.03

0

1

0

0

0

0

0

3

0

2007

9

0.06

2

0

1

0

1

1

0

4

0

2008

11

0.07

2

0

0

0

0

0

1

8

0

2009

10

0.06

1

1

0

0

1

0

2

5

0 (1)e

2010

6

0.04

2

0

0

0

2

0

0

2

0 (1)e

  1. Surveillance data 2000-2009 are obtained from annual reports "Bacterial Meningitis in the Netherlands" published by "Netherlands Reference Laboratory for Bacterial Meningitis" [5]. Data from 2010 are not published yet
  2. n.a.; not applicable
  3. a MenC disease cases are defined as culture and/or PCR-proven presence of MenC bacteria in cerebrospinal fluid and/or blood
  4. b Incidence rate is defined as the annual incidence rate of MenC disease per 100.000 inhabitants of the Netherlands
  5. c In the Netherlands, MenC conjugate vaccine was introduced in Spring 2002
  6. d The case fatality rate (CFR) calculated from 58 patients with MenC disease cases occurring between January 2003-May 2005 was 5.2% [6]
  7. e One case of MenC disease occurred in a vaccinated 16 years old female (2009), and one case in a vaccinated 19 years old male (2010). Both persons had an immune disorder